Craif announces joint research results on urological cancers (renal cell carcinoma, prostate cancer, urothelial carcinoma) at EAU 2026 (European Association of Urology)
NQ Score
100/100
AI Summary (NQ-processed)
Bio-AI startup Craif Inc. announced joint research results on urological cancers at EAU 2026 in London. The study, conducted with Keio University School of Medicine, focused on machine learning-based analysis of urinary exosomal microRNA for detection, prognostic evaluation, and immune profiling of renal cell carcinoma, prostate cancer, and urothelial carcinoma. The developed technology showed high screening accuracy and potential utility in prognosis and tumor immune status assessment.
AI analysis data is not yet available.
Frequently Asked Questions
- Q: What were the joint research results presented by Craif at EAU 2026 in London?
- A: Craif presented machine learning-based analysis of urinary exosomal microRNA for detecting renal cell carcinoma, prostate cancer, and urothelial carcinoma with high accuracy.
- Q: Which university collaborated with Craif on the urological cancer study presented at EAU 2026?
- A: Keio University School of Medicine collaborated with Craif on the machine learning-based urological cancer research presented at EAU 2026.
- Q: What technology did Craif develop for prostate cancer detection presented at EAU 2026?
- A: Craif developed a machine learning-based urinary exosomal microRNA analysis technology for prostate cancer detection presented at EAU 2026.
- Q: How accurate was Craif's screening technology for renal cell carcinoma at EAU 2026?
- A: Craif's screening technology demonstrated high accuracy for renal cell carcinoma detection based on urinary exosomal microRNA analysis at EAU 2026.
- Q: What cancer types did Craif's EAU 2026 study focus on using urinary exosomal microRNA?
- A: Craif's EAU 2026 study focused on renal cell carcinoma, prostate cancer, and urothelial carcinoma using urinary exosomal microRNA analysis.